On October 21, 2025, CERo Therapeutics announced that investigators were authorized to administer a third infusion of its lead candidate CER‑1236 to a patient in the first cohort of its Phase 1/1b AML trial. The infusion consisted of 1 million cells per kilogram, identical to the first two doses, and was completed about a week earlier. This milestone provides additional safety and dosing data for the trial.
The company also completed the first tranche of a planned $7 million financing, raising approximately $2.3 million from existing shareholders. The infusion of capital is intended to extend CERO’s cash runway and support compliance with Nasdaq listing requirements. The financing tranche is part of a broader capital raise that provides the resources needed to advance the trial and future development.
The third dose authorization is a key step in the dose‑escalation phase, allowing investigators to evaluate the feasibility of a multi‑dose strategy versus a single high‑dose approach. The data from this additional infusion will inform the recommended phase 2 dose and help determine the safety profile of CER‑1236.
Together, the clinical milestone and the financing tranche underscore CERO’s progress in moving its lead candidate forward while addressing its critical liquidity needs. The company’s ability to secure shareholder support and obtain additional funding is essential for sustaining the trial and maintaining its public company status.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.